Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.37B 3.11B 2.87B 5.45B 367B 5.54B 37.14B 14.58B 181B 14.47B 14.15B 622B P/E 2026 *
16.1x
P/E 2027 * 13.1x
Enterprise Value 3.85B 3.37B 3.11B 2.87B 5.45B 367B 5.54B 37.14B 14.58B 181B 14.47B 14.15B 622B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 5.37x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 week+0.06%
Current month+0.13%
1 month+0.35%
3 months+26.18%
6 months+35.53%
Current year+34.83%
1 week 31.45
Extreme 31.45
31.5
1 month 31.34
Extreme 31.34
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.68
Extreme 0.68
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Chairman 78 01/01/2002
Director/Board Member 62 01/10/2002
Director/Board Member 65 19/02/2015
Date Insider Type Main position Quantity % Market Cap.
06-03Fiscal year

Chief Technology Officer

3,795 0.0031%
02-17Fiscal year

Head of Human Resources

1,585 0.0013%
01-05Fiscal year

Chief Executive Officer

94,787 0.0771%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.06%+44.29%+145.86% 3.85B
-0.51%+1.57%+17.05%-7.50% 67.61B
-5.16%-8.63%+38.70%+202.12% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-1.48%-2.50%-49.86%-54.20% 40.94B
+0.12%-7.85%+48.39%-28.27% 29.4B
-10.83%-14.41%+102.94%-45.78% 27.09B
-1.53%-0.13%+70.16%+86.29% 23.32B
-2.01%-2.87%+7.20%+168.81% 19.92B
-1.59%-1.63%+64.87%+130.98% 16.91B
Average -1.77%-2.87%+38.32%+63.78% 32.36B
Weighted average by Cap. -1.62%-2.91%+31.10%+47.84%

Financials

2026 *2027 *
Net sales 636M 556M 513M 474M 900M 60.68B 915M 6.13B 2.41B 29.89B 2.39B 2.34B 103B 718M 628M 579M 535M 1.02B 68.47B 1.03B 6.92B 2.72B 33.73B 2.7B 2.64B 116B
Net income 231M 202M 186M 172M 327M 22.04B 332M 2.23B 875M 10.86B 868M 849M 37.33B 316M 277M 255M 236M 447M 30.16B 455M 3.05B 1.2B 14.86B 1.19B 1.16B 51.08B
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
10/07/26 US$31.47 0.00% 1,346,672
09/07/26 US$31.47 0.00% 1,506,797
08/07/26 US$31.47 -0.06% 4,210,590
07/07/26 US$31.49 -0.03% 780,070
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.47USD
Average target price
31.67USD
Spread / Average Target
+0.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CPRX Stock